 NEEDHAM, Mass., Sept. 06, 2022 GLOBE NEWSWIRE -- Candel Therapeutics, Inc. Nasdaq: CADL, a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences. 